International Journal of Molecular Sciences,
Год журнала:
2021,
Номер
22(22), С. 12292 - 12292
Опубликована: Ноя. 14, 2021
Estrogen
receptor-positive
(ER+)
breast
cancer
is
the
most
common
form
of
cancer.
Antiestrogens
were
first
therapy
aimed
at
treating
this
subtype,
but
resistance
to
these
warranted
development
a
new
treatment
option.
CDK4/6
inhibitors
address
problem
by
halting
cell
cycle
progression
in
ER+
cells,
and
have
proven
be
successful
clinic.
Unfortunately,
both
intrinsic
acquired
are
common.
Numerous
mechanisms
how
occurs
been
identified
date,
including
activation
prominent
growth
signaling
pathways,
loss
tumor-suppressive
genes,
noncanonical
function.
Many
successfully
targeted
demonstrate
ability
overcome
preclinical
clinical
trials.
Future
studies
should
focus
on
biomarkers
so
that
patients
likely
resistant
inhibition
can
initially
given
alternative
methods
treatment.
Nanomedicines
capable
of
delivering
multiple
drugs
have
become
essential
in
combination
therapy.
However,
the
challenges
low
drug
loading
capacity
(DLC)
and
difficulties
administering
dosages
between
different
significantly
limit
antitumor
efficacy.
In
this
study,
a
nanomedicine
constructed
through
rational
prodrug
nanocarrier
design
was
reported
for
cancer
Initially,
phenylborate
ester
(PBE)
group-modified
paclitaxel
(PTX)
(PTX-PBE)
synthesized
could
self-assemble
water.
Subsequently,
combretastatin
A4
(CA4)
polymer
conjugates,
mPEG-PCA4
(PCA4),
were
as
nanocarriers
to
facilitate
exceptionally
high
PTX-PBE
precisely
controlled
manner.
Both
vitro
vivo
experiments
demonstrated
that
PCA4
nanoparticles
(PCA4/PTX-PBE
NPs)
exhibited
potent
efficacy
favorable
biocompatibility.
Our
approach
provides
straightforward,
efficient,
controllable
strategy
co-delivery
pharmaceuticals
clinical
Cancers,
Год журнала:
2025,
Номер
17(6), С. 1039 - 1039
Опубликована: Март 20, 2025
Breast
cancer
is
the
most
frequently
diagnosed
neoplasm
in
world.
It
can
be
classified
into
four
main
subtypes,
each
of
them
showing
differences
expression
hormone
receptor
(HR),
human
epidermal
growth
factor
2
(HER2),
and
cell
metabolism.
Since
2015,
when
The
U.S.
Food
Drug
Administration
(FDA)
approved
first
cyclin-dependent
kinase
4
6
(CDK4/6)
inhibitor
that
regulates
cycle,
treatment
HR+/HER2−
BC
has
become
much
more
effective.
Currently,
palbociclib,
ribociclib,
abemaciclib
are
often
used
both
combination
with
endocrine
therapy
as
well
monotherapy.
Their
application
been
extensively
verified
many
clinical
trials
such
PALOMA-1,2,3,
MONALEESA-1,2,3,7,
MONARCH-1,2,3,
which
allowed
verification
their
effectiveness,
dosage,
adverse
effects.
Subsequent
studies,
MonarchE
NATALEE,
examined
role
these
inhibitors
adjuvant
therapy,
at
verifying
safety.
Moreover,
dalpiciclib
being
investigated
treatment.
This
article
will
summarize
efficacy,
recommendations,
toxicity
profile
between
also
discuss
possibility
using
breast
cancer.
Cells,
Год журнала:
2021,
Номер
10(6), С. 1334 - 1334
Опубликована: Май 28, 2021
Historically,
metastatic
melanoma
was
considered
a
highly
lethal
disease.
However,
recent
advances
in
drug
development
have
allowed
significative
improvement
prognosis.
In
particular,
BRAF/MEK
inhibitors
and
anti-PD1
antibodies
completely
revolutionized
the
management
of
this
Nonetheless,
not
all
patients
derive
benefit
or
durable
from
these
therapies.
To
overtake
challenges,
new
clinically
active
compounds
are
being
tested
context
clinical
trials.
CDK4/6
drugs
already
available
practice
preliminary
evidence
showed
promising
activity
also
melanoma.
Herein
we
review
literature
to
depict
comprehensive
landscape
about
We
present
molecular
genetic
background
that
might
justify
usage
drugs,
preclinical
evidence,
data,
most
ongoing
International Journal of Molecular Sciences,
Год журнала:
2021,
Номер
22(22), С. 12292 - 12292
Опубликована: Ноя. 14, 2021
Estrogen
receptor-positive
(ER+)
breast
cancer
is
the
most
common
form
of
cancer.
Antiestrogens
were
first
therapy
aimed
at
treating
this
subtype,
but
resistance
to
these
warranted
development
a
new
treatment
option.
CDK4/6
inhibitors
address
problem
by
halting
cell
cycle
progression
in
ER+
cells,
and
have
proven
be
successful
clinic.
Unfortunately,
both
intrinsic
acquired
are
common.
Numerous
mechanisms
how
occurs
been
identified
date,
including
activation
prominent
growth
signaling
pathways,
loss
tumor-suppressive
genes,
noncanonical
function.
Many
successfully
targeted
demonstrate
ability
overcome
preclinical
clinical
trials.
Future
studies
should
focus
on
biomarkers
so
that
patients
likely
resistant
inhibition
can
initially
given
alternative
methods
treatment.
